Literature DB >> 29273918

A review of atypical subtrochanteric femoral fractures in Northern Ireland between 2010 and 2014.

K J Donnelly1, A Tucker2, B Kerr3, S McDonald4, D S O'Longain1, J D Acton1.   

Abstract

The term atypical femoral fractures most commonly occur in the subtrochanteric area. Concerns exist regarding the role of bisphosphonate treatment in their aetiology. Which surgical intervention provides the best outcome remains contentious. We reviewed all atypical subtrochanteric femoral fractures treated in Northern Ireland over 5 years, specifically investigating incidence, prodromal symptoms, association with bisphosphonates and optimal fixation methods. All subtrochanteric fractures treated in the region were identified and reviewed for atypical features. Case notes and imaging were then reviewed for each patient. A total of 364 subtrochanteric femoral fractures were identified during the 5-year study period. Twenty-six of these met the criteria for an atypical fracture (7%). Thirteen patients (50%) had presented with prodromal symptoms prior to complete fracture, six of which had radiological evidence of an incomplete fracture of the lateral cortex. Thirteen patients had a history of bisphosphonate treatment. All were treated operatively, with twenty-five cephalomedullary nails and one dynamic hip screw. Twenty-one patients had follow-up for greater than 2 months, nine of which (42.9%) achieved radiological union with a mean time to union of 297 days. Dynamically locked nails had a higher union rate than statically locked (80% versus 33.3%). Four patients required major revision surgery (15.4%). The quality of reduction was statistically significant in predicting need for revision. Atypical fractures often present with prodromal symptoms. Complete fractures are difficult to successfully manage with longer than expected times to union. Treatment with a dynamically locked, cephalomedullary with a good reduction provided the best results.

Entities:  

Keywords:  Atypical; Femoral; Fracture; Management; Subtrochanteric

Mesh:

Year:  2017        PMID: 29273918     DOI: 10.1007/s00590-017-2113-7

Source DB:  PubMed          Journal:  Eur J Orthop Surg Traumatol        ISSN: 1633-8065


  46 in total

Review 1.  Bisphosphonate-associated fractures of the femur: pathophysiology and treatment.

Authors:  Thomas A Einhorn; Yelena Bogdan; Paul Tornetta
Journal:  J Orthop Trauma       Date:  2014-07       Impact factor: 2.512

2.  Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy.

Authors:  B J X Teo; J S B Koh; S K Goh; M A Png; D T C Chua; T S Howe
Journal:  Bone Joint J       Date:  2014-05       Impact factor: 5.082

3.  Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures.

Authors:  Michael B Banffy; Mark S Vrahas; John E Ready; John A Abraham
Journal:  Clin Orthop Relat Res       Date:  2011-02-25       Impact factor: 4.176

4.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

5.  Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.

Authors:  Stephen J Gomberg; Rosanna L Wustrack; Nicola Napoli; Claude D Arnaud; Dennis M Black
Journal:  J Clin Endocrinol Metab       Date:  2011-03-23       Impact factor: 5.958

6.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

Review 7.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

8.  Atypical femur fractures in patients receiving bisphosphonate therapy: etiology and management.

Authors:  Laura Blum; Karen Cummings; James A Goulet; Aaron M Perdue; Cyril Mauffrey; Mark E Hake
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-03-04

9.  Factors Affecting Time to Bony Union of Femoral Subtrochanteric Fractures Treated with Intramedullary Devices.

Authors:  Jung-Yoon Choi; Yerl-Bo Sung; Jin-Hee Yoo; Sung-Jae Chung
Journal:  Hip Pelvis       Date:  2014-06-30

10.  Bisphosphonates and atypical subtrochanteric fractures of the femur.

Authors:  N Kharwadkar; B Mayne; J E Lawrence; V Khanduja
Journal:  Bone Joint Res       Date:  2017-03       Impact factor: 5.853

View more
  2 in total

1.  The Genetics of Atypical Femur Fractures-a Systematic Review.

Authors:  Wei Zhou; Jeroen G J van Rooij; Peter R Ebeling; Annemieke J M H Verkerk; M Carola Zillikens
Journal:  Curr Osteoporos Rep       Date:  2021-02-15       Impact factor: 5.096

Review 2.  Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures.

Authors:  Jessica Starr; Yu Kwang Donovan Tay; Elizabeth Shane
Journal:  Curr Osteoporos Rep       Date:  2018-08       Impact factor: 5.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.